Item 3.02. Unregistered Sales of Equity Securities
As of March 2, 2022, 75,257,511 warrants, the resale of the underlying shares of
which were registered on H-Cyte, Inc.'s (the "Company") Registration Statement
on Form S-1 (File No. 333-262553), had been exercised, including 41,608,884
warrants held by FWHC Bridge, LLC, an affiliate of the Company and the Company's
principal shareholder, for aggregate gross proceeds of $1,053,605. In connection
with the exercise, the holders received from the Company immediately exercisable
inducement warrants (the "Inducement Warrants"), providing for a five-year term
and an exercise price of $0.014, on a one-to-one basis with the Warrants that
were exercised. The Company will use the proceeds of the warrant exercise for
working capital purposes.
The Inducement Warrants were issued in reliance upon an exemption from
registration pursuant to 4(a)(2) under the Securities Act of 1933, as amended,
and Rule 506 of Regulation D promulgated thereunder.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits.
The following exhibit is filed as part of this report:
Exhibit
No. Description
4.1 Form of Inducement Warrant
Cover Page Interactive Data File (embedded within the Inline XBRL
104 document)
© Edgar Online, source Glimpses